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A B S T R A C T
Adrenomedullin (ADM) is a vasoactive peptide expressed in several peripheral organs and known primarily for
its beneﬁcial vasoactive eﬀects. However, ADM is also known to inhibit insulin secretion, and central admin-
istration of ADM has been shown to elicit anorexigenic eﬀects. Here, we investigated if peripheral co-admin-
istration of ADM and glucagon-like peptide 1 (GLP-1) could subdue the hypoglycaemic eﬀects of ADM while
enhancing its anorectic properties.
The eﬀects of mono- and combination therapy of ADM and GLP-1 on appetite regulation and glucose
homeostasis were assessed acutely in male NMRI mice for 12 h, while eﬀects on glucose homeostasis were
assessed by oral glucose tolerance tests (OGTT).
While the monotherapy with GLP-1 and ADM resulted in modest anorexigenic eﬀects, co-administration of
the two peptides led to a marked additive reduction in food intake. Moreover, while OGTT-evoked blood glu-
cose-excursions were signiﬁcantly increased by ADM monotherapy, co-administration of ADM with a lower dose
of GLP-1 normalized glucose excursions.
In conclusion, we demonstrate additive anorectic eﬀects of ADM and GLP-1, and that GLP-1 co-administration
prevents ADM-induced impairment of glucose tolerance, suggesting that ADM could be potential anti-obesity
target when combined with GLP-1 agonist therapy.
1. Introduction
Adrenomedullin (ADM) is a 52-amino acid peptide hormone be-
longing to the calcitonin gene-related peptide (CGRP) superfamily and
is primarily secreted by endothelial- and vascular smooth muscle cells
[1]. Humans have two adrenomedullin receptors, ADM1 and ADM2,
both being hetero-dimers of the calcitonin receptor-like receptor (CLR)
and receptor activity-modifying protein (RAMP) 2 and 3, respectively
[2]. In addition, ADM might have cross-reactivity with other CGRP
receptor family members, especially the CGRP receptor, a heterodimer
of CLR and RAMP1 [2]. In humans, ADM have been found to increase
cardiac output, induce hypotensive eﬀects and elicit vasoprotection
[1,3,4], and these vasoactive eﬀects have spurred interest in developing
ADM as a novel cardioprotective treatment concept [4,5]. Interestingly,
ADM has also been proposed to exert eﬀects on glucose homeostasis
and food intake. However, whether ADM constitutes an attractive
target within diabetes and obesity treatment is presently unclear
[6–14].
Previous studies in animal models have shown that glucose home-
ostasis is negatively inﬂuenced by ADM through the inhibition of in-
sulin secretion [7,14]. Thus, in rats, intravenous administration of ADM
delays glucose-stimulated insulin responses resulting in elevated blood
glucose levels [6,7]. Furthermore, a subset of diabetic patients has been
found to have increased plasma concentrations of ADM, indicating
further that ADM may play a causative role in the development of
diabetes type 2 [6,14–16]. Preclinical and clinical studies have also
revealed that ADM plasma concentrations are positively correlated to
body weight gain and that ADM expression is increased in adipose
tissues [12,13,17,18]. Conversely, weight loss may lead to reduced
circulating ADM levels as demonstrated after Roux-en-Y gastric bypass
(RYGB) surgery in morbidly obese subjects [17]. Finally, studies in
chicks and rats have indicated a short-lasting food intake inhibitory
eﬀect of ADM following either central administration [10,11] or in-
travenous infusion [19]. Collectively, these data suggest that ADM may
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constitute a target within diabetes and obesity treatment.
The mechanistic basis for the anorectic and glucose regulatory of
ADM is presently not clear. It has been suggested that the anorectic
properties may be partly mediated through a direct activation of cen-
trally located CGRP receptors, which leads to an inhibition of gastric
emptying and increased sensation of satiety [10,20]. However, this
hypothesis relies on antagonistic studies using CGRP8-37, which also
antagonize other members of the CGRP receptor family including the
ADM receptors, albeit at a lower potency [2]. Conversely, activation of
ADM receptors expressed in the islets of the pancreas is believed to be
directly involved in the insulin regulatory properties [14,21].
The eﬀects of ADM on glucose and body weight homeostasis are in a
way similar to the metabolic eﬀects of glucagon, which also raise blood
glucose levels and reduce food intake [22]. Interestingly, GLP-1 and
glucagon co-agonism has been shown to induce enhanced metabolic
eﬀects and is currently pursued by several pharmaceutical companies as
a new therapeutic treatment for diabetes and obesity (for a review, see
[23]). Similarly, synergy or additivity with GLP-1 has been demon-
strated for several other satiety-regulatory peptides, including the
amylin analogue salmon calcitonin [24], another member of the CGRP-
superfamily albeit with diﬀerent receptor preferences. A combined dose
(s.c.) of salmon calcitonin and a GLP-1R agonist (exendin-4) have been
reported to provide synergetic anorectic eﬀects in non-human primates
[25]. With this in mind, we were curious to examine if GLP-1 co-
agonism could subdue the hypoglycaemic eﬀects of ADM while en-
hancing its anorectic properties.
2. Materials & methods
2.1. Animals
Male NMRI mice (5 weeks of age, 25–30 g) were purchased from
Taconic (Denmark). Following acclimatization (5 mice per cage), NMRI
mice were single-housed for oral glucose tolerance tests (OGTT) or
group-housed (four per cage) for automated real-time food intake
monitoring (12/12 h light-dark cycle, lights oﬀ at 01:00 PM; tempera-
ture: 22 ± 2 °C; 50% relative humidity). Animals had ad libitum access
to regular chow (Altromin 1324, Brogaarden, Denmark) and domestic-
quality tap water.
All animal experiments were conducted in accordance to inter-
nationally accepted principles for the care and use of laboratory ani-
mals. The experiments were covered by a license (2013-15-2934-
00784) issued by the Danish Animal Experiments Inspectorate.
2.2. Peptide synthesis
Human native ADM and GLP-1(7–37)−OH were synthesized using
fully automated, standard Fmoc-based solid-phase peptide synthesis on
a SyroII peptide synthesizer (Biotage AB, Sweden) with reagents from
Iris Biotech GmbH (Germany) or Sigma Aldrich (Denmark). Crude
peptides were puriﬁed using reversed-phase HPLC, quantiﬁed and
characterized by LC–MS (Acquity UPLC equipped with a SQD2 mass
spectrometer, Waters, Denmark). Subsequently, the disulphide bridge
of ADM was formed using 1.2 eq. aldrithiol (Sigma, Denmark) after
which ADM was again puriﬁed by C18 reversed-phase HPLC. The ﬁnal
purities of both GLP-1 and ADM were above 95% as determined by
UPLC.
2.3. Compounds
For oral glucose tolerance studies, the vehicle consisted of 10%
DMSO in water. In the food intake studies, the vehicle consisted of 10%
DMSO in water with linagliptin (212 nmol/mL; 0.5 mg/kg, Toronto
Research Chemicals, Canada) to extend the half-life of GLP-1 [26].
Compounds were administrated at 5–10mL/kg.
2.4. Acute food intake
Real-time food intake of mice was monitored using a fully auto-
mated food intake monitoring system (HM-2; MBRose ApS, Denmark).
Animals were randomized to treatment (n=8 per group) based on
baseline body weight. Animals were fasted for four hours prior to
dosing. Animals were dosed s.c. 30min prior to lights out, and food
intake data were collected automatically for a total of 18 h post-dosing.
2.5. Oral glucose tolerance test (OGTT)
The single housed mice were randomized to treatment (n=8 per
group) according to body weight on day -1. On the day of the OGTT
(day 0), animals were fasted for four hours prior to the test. Animals
were dosed s.c. with vehicle or compound 30min before receiving an
oral glucose load (2 g/kg, at t= 0). Blood glucose was measured from
tail vein blood samples at time points before glucose administration
(t= -30min) and after glucose administration (t= 15, 30, 60, 120, and
240min). Blood samples were collected into 10 μl heparinized glass
capillary tubes, immediately suspended in buﬀer (0.5 mL of glucose/
lactate system solution) and analysed for glucose concentrations on the
test day using a BIOSEN c-Line glucose meter according to manu-
facturer’s instructions (EKF-diagnostics, Germany).
For analysis of insulin, blood samples were collected at t= 60 and
240min to microvettes with anticoagulant. Subsequently, samples were
mixed by inversion 5 times and plasma was isolated by centrifugation
(3000 g, 10min, 4 °C). Plasma insulin was measured in duplicate using
a single-plex assay (Meso Scale Diagnostics, USA) according to the
manufacturer’s instructions.
2.6. Statistics
Data were analysed using GraphPad Prism (v7.0, Graphpad
Software, USA). Results are presented as mean ± standard error of
mean (S.E.M.). For statistical analysis, one-way ANOVA against the
vehicle group with Bonferroni’s post-hoc test (Bar-graphs; Food intake,
OGTT-AUC, plasma insulin), or two-way ANOVA against the vehicle
group with Bonferroni's post-hoc test (time-response data on body-
weight and OGTT) was used. P-values< 0.05 were considered statis-
tically signiﬁcant.
3. Results
3.1. ADM reduces food intake in NMRI mice
ADM (3000 nmol/kg, s.c.) signiﬁcantly reduced food intake at
1–3 h post-dosing but the eﬀect had worn oﬀ at the 12-hour measuring
point (Fig. 1A–C). The magnitude and duration of the food intake
suppressive eﬀect of ADM was comparable to an equivalent dose of
GLP-1 (3000 nmol/kg, s.c.).
3.2. ADM impairs glucose tolerance in NMRI mice
ADM (3000 nmol/kg, s.c.) signiﬁcantly increased glucose excursion
at t= 60 and 120min (p < 0.001) compared to vehicle controls
(Fig. 1D). The eﬀect was also reﬂected in the corresponding glucose-
AUC values (0–120min, p < 0.01) (Fig. 1E). Conversely, GLP-1
(300 nmol/kg, s.c.) reduced blood glucose levels at all timepoints
measured, as well as glucose-AUC (0–120min, p < 0.001) (Fig. 1D–E).
3.3. ADM potentiates the anorectic eﬀect of GLP-1 in NMRI mice
A high dose of GLP-1 (3000 nmol/kg, s.c.) signiﬁcantly reduced food
intake throughout the study period, while a lower dose (1000 nmol/kg,
s.c.) was eﬀective only during the ﬁrst hour post-dosing (Fig. 2). A low
dose of ADM (1000 nmol/kg, s.c.) did not signiﬁcantly inﬂuence food
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intake although animals tended to eat less than the vehicle animals;
particularly in the ﬁrst hour post-dosing. In contrast, combined treat-
ment with the low doses of ADM and GLP-1 signiﬁcantly suppressed
food intake in NMRI mice, as compared to vehicle controls (p < 0.05,
Fig. 2). The co-administration of ADM (1000 nmol/kg, s.c.) with a
higher dose of GLP-1 (3000 nmol/kg, s.c.) augmented the anorectic
actions (Fig. 2). The additive anorectic eﬀects of ADM and GLP-1 were
most pronounced 1–3 h post-dosing but remained throughout the entire
monitoring period.
3.4. GLP-1 prevents impaired glucose tolerance in ADM-treated NMRI mice
The eﬀects of ADM on glucose homeostasis were assessed in the
context of monotherapy, as well as in combination with GLP-1 ad-
ministration. When administered alone, ADM dose-dependently
(300–1000 nmol/kg, s.c.) impaired glucose tolerance in NMRI mice
(Fig. 3A). Administration of 300 nmol/kg (s.c.) resulted in elevated
blood glucose levels at t= 30 and 60min (p < 0.001; Fig. 3A), and
glucose excursions were further augmented when administering a
moderate dose of ADM (1000 nmol/kg, s.c.). The eﬀect of a moderate
dose of ADM (1000 nmol/kg, s.c.) on glucose excursions was compar-
able to that attained by a higher dose of ADM (3000 nmol/kg, s.c.) and
resulted in a similar area-under-the-curve 120min post dosing (Figs. 1E
& 3 B). Additionally, ADM appeared to reduce or delay glucose-sti-
mulated plasma insulin levels, with insulin levels being slightly reduced
as compared to vehicle treated animals at t= 60min of the OGTT
Fig. 1. ADM and GLP-1 reduces acute food intake but have opposing eﬀects on oral glucose tolerance in lean NMRI mice. (A–C) Acute cumulative food intake of lean
NMRI mice administered with vehicle, ADM or GLP-1 measured 1, 3, and 12 h post-dosing (10mL/kg, 3000 nmol/kg). (D) Blood glucose excursion curves of lean
NMRI mice during an OGTT. Vehicle, ADM (3000 nmol/kg), and GLP-1 (300 nmol/kg) were administered (5mL/kg) 30min prior to the glucose bolus. (E) Area-
under-the-curve (AUC 0–120min) calculated from the glucose excursion curves. Statistics: *p < 0.5, **p < 0.01, ***p < 0.001 vs. vehicle derived from either one-
way ANOVA with Bonferroni’s post hoc test (A, B, C, and D) or two-way ANOVA with Bonferroni’s post hoc test (E).
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(Fig. 3C). However, the reduction was not found to be signiﬁcant
(p=0.09).
As expected, GLP-1 (30 nmol/kg, s.c.) decreased blood glucose le-
vels at t= 15, 30 and 60min (p < 0.001) as well as the glucose-AUC
(0–120min, p < 0.001) compared to vehicle controls (Fig. 3A). Co-
administration of GLP-1 (30 nmol/kg, s.c.) and ADM (1000 nmol/kg,
s.c.) fully prevented the reduced glucose tolerance aﬀorded by ADM
administration alone (Fig. 3A). This eﬀect was also reﬂected by nor-
malized insulin responses in the OGTT upon combined ADM and GLP-1
administration (Fig. 3C). No treatment aﬀected blood-glucose or insulin
levels 240min after the glucose bolus (Fig. 3A & D).
4. Discussion
Whereas the vasoactive properties of ADM have been well char-
acterized, less is known about the metabolic eﬀects of ADM. Here, we
demonstrated that acute systemic ADM administration suppressed food
intake and impaired glucose tolerance in mice. Furthermore, we
demonstrated for the ﬁrst time that GLP-1 and ADM acted additively to
reduce food intake in an acute setting, and that GLP-1 prevented re-
duced oral glucose tolerance following acute ADM administration in
lean mice.
An anorectic response to acute administration ADM has previously
been reported following central administration and i.v. infusion in rats.
In line with this, we found that subcutaneous administration of ADM
had an inhibitory eﬀect on the acute food intake of mice, being equi-
eﬃcacious to GLP-1. In addition, and in contrast to GLP-1, we de-
monstrated that s.c. ADM administration led to increased glucose ex-
cursions in an OGTT. Hence, ADM and GLP-1 had opposing eﬀects on
glucose homeostasis. A similar ﬁnding has been reported by Martínez
and co-workers who demonstrated how i.v. administration of ADM to
rats increased glucose excursions by delaying glucose-stimulated in-
sulin release [7].
Based on these data, we hypothesized that co-administration of
ADM with GLP-1 could attenuate ADM’s insulin suppressing eﬀects and
potentially augment its anorectic properties. GLP-1 is a powerful
Fig. 2. ADM and GLP-1 shows additive inhibitory eﬀects on food intake in NMRI mice. (A–D) Acute eﬀects on food intake measured 1, 3, and 12 h after dosing (5mL/
kg) with vehicle, GLP-1 (1000–3000 nmol/kg), ADM (1000 nmol/kg), and combinations of these (ADM 1000 nmol/kg+GLP-1 1000–3000 nmol/kg). For ﬁgure A,
shaded area represents the dark phase, and lines beneath graphs indicates p < 0.05 vs. vehicle derived from a two-way ANOVA with Bonferroni’s post hoc test. For
ﬁgure B–D, *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle derived from one-way ANOVA with Bonferroni’s post hoc test.
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incretin that reduces blood glucose levels through the ampliﬁcation of
insulin secretion in response to increased blood glucose levels, and is
known to reduce food intake by central mechanisms of action [27–29].
In line with this hypothesis, we observed that ADM and GLP-1 acted
additively to reduce food intake in an acute setting. This additive an-
orectic eﬀect was most marked in the ﬁrst few hours post dosing where
it led to a near abolishment of cumulative food intake. The relative
short-acting eﬀects of ADM and GLP-1 are in agreement with the short
circulatory half-lives of native GLP-1 (t1
2




In respect to blood glucose homeostasis, we found that GLP-1 co-
administration abolished the unfavourable eﬀects of ADM on glucose
homeostasis in lean mice. In an OGTT, ADM treated mice were found to
have a dose-dependent increase in glucose excursions, coupled to a
delayed glucose-stimulated insulin response, whereas low dose GLP-1
monotherapy did not aﬀect insulin levels but blunted glucose excur-
sions. Co-administration of ADM and a low dose of GLP-1 led to OGTT-
evoked insulin responses identical to that observed for GLP-1
monotherapy (Fig. 3D–E). Thus, GLP-1 was able to fully prevent ADM’s
negative eﬀects on glucose tolerance, even when administered in a
much lower dose than ADM (30 nmol/kg vs 1000 nmol/kg).
The molecular mechanisms underlying ADM’s anorectic eﬀects are
poorly understood. Taylor and co-workers found that anorectic eﬀects
observed following central administration of ADM in rats could be re-
duced by 50% through concomitant i.c.v. administration of the CGRP
receptor family antagonist CGRP8-37 [10]. Likewise, Martinez and col-
leagues reported that central administration of ADM (75–150 pmol/rat)
inhibited gastric emptying in rats while an i.v. dose (150 pmol/rat) did
not [20]. The ADM-mediated eﬀects on gastric emptying rates could be
fully restored by i.c.v. administration of CGRP8-37 [20]. Together, this
indicates that ADM’s eﬀect on acute food intake is mediated through
central CGRP receptors. However, since CGRP8-37 does not exclusively
inhibit the CGRP receptor, but all receptors in the CGRP family, acti-
vation of central ADM1/2 receptors cannot be excluded [2]. Ad-
ditionally, more research is needed to fully understand the insulin
suppressive properties of ADM. Mulder and co-workers showed how
Fig. 3. GLP-1 prevents ADM-induced impaired glucose tolerance in NMRI mice (A) Glucose excursion curves in NMRI mice after dosing (5mL/kg) with vehicle, ADM
(300 or 1000 nmol/kg), native GLP-1 (30 nmol/kg) or a combination of ADM (1000 nmol/kg) and GLP-1 (30 nmol/kg). Animals were dosed 30min prior to the
glucose bolus. (B) Area-under-the-curve (AUC 0–120min) calculated from the glucose excursion curves. (C & D) Plasma insulin levels during an oral glucose
tolerance test at t= 60min and t= 240min. *p < 0.05, ***p < 0.001 vs. vehicle derived from two-way ANOVA with Bonferroni’s post hoc test (A) or one-way
ANOVA with Bonferroni’s post hoc test (B–D).
E.M. Bech et al. Biomedicine & Pharmacotherapy 109 (2019) 167–173
171
nanomolar concentrations of ADM promoted insulin secretion in iso-
lated rat islets [31]. Contrarily, other studies have found that ADM
inhibited insulin secretion in INS-1 cells and in isolated rat- and mouse
islets [7,14,32], possibly through inhibition of exocytosis from pan-
creatic β-cells through activation of pertussis-toxin sensitive Gi/o pro-
teins [14]. The demonstration that ADM delayed OGTT-evoked insulin
release and increased glucose excursions in rats [6,7] and in mice,
supports the latter. Thus, ADM’s eﬀects on insulin secretion may bal-
ance between inhibitory and stimulatory depending on concentration,
but at the pharmacological doses applied in vivo ADM appears to inhibit
insulin secretion. Finally, it is presently not known if secondary eﬀects
of ADM contributed to the anorexia, hyperglycaemia, and insulin in-
hibition observed in this study. For example, intravenous administra-
tion of ADM is known to yield an acute hypotensive response in an-
esthetized mice at 12 nmol/kg lasting for 3–5min [33]. To sustain
hemodynamic stability, hypotension might lead to a rise in sympathetic
tone, which in turn has been linked to hepatic glucose release and a
reduction in insulin release [34]. In this study, ADM were investigated
in non-anesthetized animals and administrated s.c., which will protract
circulatory absorption. However, despite the deviations in conduction
of the two studies, it cannot be ruled out that the observed eﬀects at
least partly can be ascribed to hypotension. Further studies are needed.
Peptides with GLP-1 additivity or synergy are of high interest for the
development of better treatments against obesity and diabetes - parti-
cularly, chimeric peptides acting on two-three distinct receptors may
elicit beneﬁts beyond those achievable with monotherapies [35]. Our
results with ADM GLP-1 co-administration lends rationale to a com-
bined ADM and GLP-1 peptide, which could potentially elicit GLP-1′s
positive eﬀects on blood glucose homeostasis while reducing food in-
take further than mono-therapy. Furthermore, ADM is known to elicit
hypotensive and cardioprotective eﬀects [1,3,36–38] and, thus, a ADM
GLP-1 chimer might boost the positive cardiovascular eﬀects already
observed for marketed GLP-1 agonists [39]. However, further studies
including chronic evaluation in diet- or genetically induced obese an-
imal models are required to further access the potential of ADM/GLP-1
co-agonism for the treatment of obesity
5. Conclusion
In conclusion, we validated the acute eﬀects of native ADM on food
intake and glucose homeostasis in lean mice following peripheral ad-
ministration. Additionally, co-administration of ADM and GLP-1 pro-
moted additive inhibitory eﬀects on food intake and prevented ADM-
induced impairment of glucose tolerance. Consequentially, ADM if
combined with GLP-1 could be interesting as a potential target for the
treatment of obesity.
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